| Sarah Frank, | |
|
511 Jermor Ln, Ste 102, Westminster, MD 21157-6152 | |
| (410) 871-2494 | |
| Not Available |
| Full Name | Sarah Frank |
|---|---|
| Gender | Female |
| Speciality | Qualified Speech Language Pathologist |
| Experience | 9 Years |
| Location | 511 Jermor Ln, Westminster, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023643236 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 08244 (Maryland) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Accessible Speech Therapy, Llc | 7214344282 | 2 |
News Archive
Solta Medical, Inc., a global leader in the medical aesthetics market, today announced results for the fourth quarter ended December 31, 2012. Revenue for the fourth quarter was $39.8 million, an increase of $6.6 million, or 20%, as compared to the fourth quarter of 2011.
APR announces the grant of the European CE approval of Nexodyn, a newly developed innovative product intended for use in a variety of wound conditions such as acute wounds, burns and advanced ulcers including venous and pressure ulcers and diabetic foot ulcers.
Patients suffering from a devastating disease are being given fresh hope through an innovative trial being led by the Sheffield Institute for Translational Neuroscience (SITraN) and Sheffield Teaching Hospitals.
Researchers at MIT, the Broad Institute and Rockefeller University have developed a new technique for precisely altering the genomes of living cells by adding or deleting genes.
A drug that suppresses the immune system and reduces inflammation has been shown to be effective in treating lung disease associated with the devastating connective tissue disease scleroderma, according to results presented at the American Thoracic Society International Conference on May 23.
› Verified 1 days ago
| Provider Name | Accessible Speech Therapy, Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1689267064 PECOS PAC ID: 7214344282 Enrollment ID: O20210319000113 |
News Archive
Solta Medical, Inc., a global leader in the medical aesthetics market, today announced results for the fourth quarter ended December 31, 2012. Revenue for the fourth quarter was $39.8 million, an increase of $6.6 million, or 20%, as compared to the fourth quarter of 2011.
APR announces the grant of the European CE approval of Nexodyn, a newly developed innovative product intended for use in a variety of wound conditions such as acute wounds, burns and advanced ulcers including venous and pressure ulcers and diabetic foot ulcers.
Patients suffering from a devastating disease are being given fresh hope through an innovative trial being led by the Sheffield Institute for Translational Neuroscience (SITraN) and Sheffield Teaching Hospitals.
Researchers at MIT, the Broad Institute and Rockefeller University have developed a new technique for precisely altering the genomes of living cells by adding or deleting genes.
A drug that suppresses the immune system and reduces inflammation has been shown to be effective in treating lung disease associated with the devastating connective tissue disease scleroderma, according to results presented at the American Thoracic Society International Conference on May 23.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sarah Frank, 511 Jermor Ln, Ste 102, Westminster, MD 21157-6152 Ph: (410) 871-2494 | Sarah Frank, 511 Jermor Ln, Ste 102, Westminster, MD 21157-6152 Ph: (410) 871-2494 |
News Archive
Solta Medical, Inc., a global leader in the medical aesthetics market, today announced results for the fourth quarter ended December 31, 2012. Revenue for the fourth quarter was $39.8 million, an increase of $6.6 million, or 20%, as compared to the fourth quarter of 2011.
APR announces the grant of the European CE approval of Nexodyn, a newly developed innovative product intended for use in a variety of wound conditions such as acute wounds, burns and advanced ulcers including venous and pressure ulcers and diabetic foot ulcers.
Patients suffering from a devastating disease are being given fresh hope through an innovative trial being led by the Sheffield Institute for Translational Neuroscience (SITraN) and Sheffield Teaching Hospitals.
Researchers at MIT, the Broad Institute and Rockefeller University have developed a new technique for precisely altering the genomes of living cells by adding or deleting genes.
A drug that suppresses the immune system and reduces inflammation has been shown to be effective in treating lung disease associated with the devastating connective tissue disease scleroderma, according to results presented at the American Thoracic Society International Conference on May 23.
› Verified 1 days ago
Karie Hadley, PHD Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 125 N Court St, Westminster, MD 21157 Phone: 410-751-3644 | |
Therafit Enterprises, Inc. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 511 Jermor Ln Ste 102, Westminster, MD 21157 Phone: 410-871-2494 | |
Wendy Beth Blum, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 125 N Court St, Westminster, MD 21157 Phone: 410-751-3033 | |
Adriana Millan, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 125 N Court St, Westminster, MD 21157 Phone: 410-751-3033 | |
Brittany D Kauffman, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 125 N Court St, Westminster, MD 21157 Phone: 410-751-3033 | |
Ms. Mary Keelinn Leatherman, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 200 Memorial Ave, Westminster, MD 21157 Phone: 410-848-3000 |